News
DGAP-News: BB BIOTECH AG: Increased investment level balanced by established core holdings
Annual General Meeting - Shareholders approve all proposals of the Board of Directors
Kuros Biosciences's MagnetOs Flex Matrix Cleared by FDA for Spinal Indications
Evolva achieves important product-related milestones with global customer, triggering revenues of more than 20% of FY21 total revenues
AEVIS VICTORIA SA - Ordinary General Meeting of Shareholders on 28 April 2022
AEVIS VICTORIA SA - Ordentliche Generalversammlung vom 28. April 2022
DIAMOND trial: Veltassa® enables patients to achieve long-term potassium control and optimized RAASi therapy
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma today announced full results from its phase-IIIb DIAMOND trial showing that Veltassa® allowed patients to achieve
AEVIS VICTORIA SA achieved very strong results on its investments in 2021 with a holding income of CHF 216.4 million and a net profit of CHF 197.6 million
AEVIS VICTORIA SA erzielte im Jahr 2021 ein sehr gutes Ergebnis mit ihren Beteiligungen, bei einem Ertrag von CHF 216.4 Millionen und einem Reingewinn von CHF 197.6 Millionen auf Holdingebene
Publication of definitive end result for Vifor Pharma tender offer
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220327005085/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
CSL
Publication of provisional end result for Vifor Pharma tender offer: Participation rate of 94 percent
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322006149/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
CSL
AEVIS VICTORIA SA verkauft Medgate-Beteiligung an Otto Group
AEVIS VICTORIA SA sells its participation in Medgate to Otto Group
AEVIS VICTORIA SA (AEVS:SW) erzielt 2021 einen Umsatz CHF 895.9 Millionen, 22.2% über Vorjahr
AEVIS VICTORIA SA (AEVS:SW) announces 2021 revenues of CHF 895.9 million, up by 22.2%
Publication of definitive Interim Result for Vifor Pharma tender offer: CSL Behring AG declares offer successful
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220307005938/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
CSL
Publication of provisional interim result for Vifor Pharma tender offer: Participation rate of 74 percent
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220302006217/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
CSL
AEVIS VICTORIA SA (AEVS:SW): Division Hospitality erwirbt Hotel L'Oscar im Zentrum von London für GBP 60 Millionen.
AEVIS VICTORIA SA (AEVS:SW): Hotel division acquires hotel L'Oscar in central London for GBP 60 million.
Neue Behandlungsoption für Patienten mit SHPT – Rayaldee® in der Schweiz ab sofort verfügbar
Vifor Pharma Schweiz AG gab heute die Markteinführung des Calcifediol-Retardpräparats Rayaldee® in der Schweiz bekannt. Rayaldee® ist die erste und einzige in Europa zugelassene orale Therapie
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220227005069/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
Vifor Pharma reports sustained growth in 2021
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma Group reported a solid performance in 2021 and an increase in profitability, supported by a strong recovery in Ferinject
Vifor Pharma Gruppe erzielt nachhaltiges Wachstum in 2021
Regulatory News:
AD HOC-MITTEILUNG GEMÄSS ART. 53 KR
Die Vifor Pharma Gruppe verzeichnete 2021 eine solide Geschäftsentwicklung und eine Steigerung der Profitabilität, die von einer starken
Vifor Pharma gibt Markteinführung von Tavneos® in Deutschland bekannt
Vifor Pharma Deutschland GmbH hat heute die Markteinführung von Tavneos® bekannt gegeben, der ersten in Europa zugelassenen oralen Therapie für die Behandlung der beiden Haupttypen von
Vifor Pharma appoints two new members to the Executive Committee
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma Group today announced the appointment of acting Chief Financial Officer Alexandros Sigalas and Group General Counsel Dr